-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Professor Mao Ying and others from the Department of Neurosurgery of Huashan Hospital affiliated to Fudan University reported that Professor Mao Ying's team recruited 111 patients with glioma and matching healthy individuals, applied 5hmC-Seal technology to detect the expression level of 5hmC in circulating free DNA (cfDNA), and analyzed its characteristics in terms of glioma diagnosis grading, gene mutation, pathological diagnosis and related biology.
In addition, GO and KEGG analysis were applied to explore the role
of 5hmC and differentiating genes and pathways.
The article was published online in April 2021 in Neuro-Oncology Advances
.
——Excerpt from the article chapter
【Ref: Cai J, et al.
Research background
Gliomas are common malignancies of the central nervous system and have poor
clinical outcomes in patients due to their high degree of intervariance and invasion.
5-Hydroxymethylcytosine (5-hydroxymethylcytosine, 5hmC) is a non-invasive biomarker for the diagnosis of cancer, with gene regulation and tissue specificity, and can be analyzed
by 5hmC-Seal technology.
Professor Mao Ying and others from the Department of Neurosurgery of Huashan Hospital affiliated to Fudan University reported that Professor Mao Ying's team recruited 111 patients with glioma and matching healthy individuals, applied 5hmC-Seal technology to detect the expression level of 5hmC in circulating free DNA (cfDNA), and analyzed its characteristics in terms of glioma diagnosis grading, gene mutation, pathological diagnosis and related biology.
In addition, GO and KEGG analysis were applied to explore the role
of 5hmC and differentiating genes and pathways.
The article was published online in April 2021 in Neuro-Oncology Advances
.
Results of the study
The findings suggest that the median age of the newly diagnosed 111 patients with glioma was 49.Conclusion of the study
In summary, the application of non-invasive 5hmC-Seal technology can comprehensively analyze 5hmC in cfDNA as an important basis for the diagnosis and classification of gliomas.
It is used in the routine screening and disease monitoring of gliomas, providing an important tool
for the early detection and precise treatment of glioma patients.
